Last reviewed · How we verify
NCT03696485
Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS
Phase 1, PHASE2 trial testing SCM-010 in Secondary Progressive Multiple Sclerosis (SPMS). Withdrawn.
1 February 2025
Quick facts
| Lead sponsor | Stem Cell Medicine Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 February 2024 |
| Primary completion | 1 February 2025 |
| Estimated completion | 1 February 2025 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- SCM-010 — full drug profile →
Conditions studied
- Secondary Progressive Multiple Sclerosis (SPMS) — all drugs for Secondary Progressive Multiple Sclerosis (SPMS) →
Sponsor
Stem Cell Medicine Ltd. — full company profile →
Who can join
Adults 18 to 60, any sex, with Secondary Progressive Multiple Sclerosis (SPMS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective, single center, open label, phase I/IIa escalating dose study. To evaluate the safety and efficacy of escalating doses of SCM-010 in subjects with SPMS.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Advances in the Treatment of Multiple Sclerosis.
Goldschmidt C, McGinley MP. · · 2021 · cited 44× · PMID 33223085 · DOI 10.1016/j.ncl.2020.09.002 -
Stem Cell Therapies for Progressive Multiple Sclerosis.
Smith JA, Nicaise AM, Ionescu RB, Hamel R, et al · · 2021 · cited 32× · PMID 34307372 · DOI 10.3389/fcell.2021.696434 -
Advanced Progress in the Role of Adipose-Derived Mesenchymal Stromal/Stem Cells in the Application of Central Nervous System Disorders.
Wu H, Fan Y, Zhang M. · · 2023 · cited 17× · PMID 38004615 · DOI 10.3390/pharmaceutics15112637 -
A focus on allogeneic mesenchymal stromal cells as a versatile therapeutic tool for treating multiple sclerosis.
Shokati A, Naser Moghadasi A, Nikbakht M, Sahraian MA, et al · · 2021 · cited 13× · PMID 34256857 · DOI 10.1186/s13287-021-02477-5
Verify or expand the search:
- PubMed search for NCT03696485
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Secondary Progressive Multiple Sclerosis (SPMS)
Currently open trials in the same condition.
- NCT07225504 — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03696485 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stem Cell Medicine Ltd.
- Last refreshed: 18 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03696485.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing